bgb-16673
bgb-16673: 3 clinical trials tracked.
bgb-16673 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about bgb-16673, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (3)
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors
Primary endpoint: Progression-Free Survival (PFS) by IRC
A Phase 1, Open-label, Fixed-sequence, Crossover Study to Investigate the Effect of Coadministration of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-16673 in Healthy Participants
Primary endpoint: Part A and Part B: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
Primary endpoint: Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)